BENZODIAZEPINE TRANQUILIZERS AS A "GOLD STANDARD" FOR THE TREATMENT OF PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME (LITERATURE REVIEW)

Abstract

The article presents a review of modern scientific publications related to the use of benzodiazepine tranquilizers in the treatment of patients with alcohol withdrawal syndrome (AWS). More
than 50 % of alcohol<consuming patients who need pharmacological treatment have the symptoms of AWS. Benzodiazepines are the medications of choice for the treatment of anxiety, fear,
and emotional tension within AWS. However, therapy is often ineffective and some patients develop dose<dependent adverse drug reactions (ADRs), which reduce the treatment efficacy for
this category of patients.
Objective: to systematize scientific data on the use of benzodiazepines in the treatment of patients with alcohol withdrawal syndrome (AWS).
Objectives: To analyze publications on the use of benzodiazepine tranquilizers in the treatment of patients with AWS. To summarize the results of pharmacoepidemiological studies on the
frequency of occurrence of ineffective cases of treatment with AWS tranquilizers, and cases of development of dose<dependent adverse drug reactions (ADR). To analyze the reasons that
can influence the individual response of benzodiazepine therapy, worsening the effectiveness and safety.
Conclusions: The individual characteristics of the patient, both associated with the clinic of SOA and with the polymorphism of genes encoding elements of the pharmacokinetics and
pharmacodynamics of drugs, can affect the effectiveness and safety of therapy with benzodiazepine tranquilizers.
Research Material and Methods: Representative research databases PubMed and Google Scholar were used as research material. A literature search was conducted between 2010
and 2019. The following words and combinations were used as search tools: alcohol withdrawal, AWS, benzodiazepines, BDZ, diazepam, lorazepam, alcoholism, alcohol addiction, alcohol
dependence, alcohol abuse, alcohol use disorder.